ABSTRACT Inference of the insulin secretion rate (ISR) from C-peptide measurements as a quantification of pancreatic b-cell function is clinically important in diseases related to reduced insulin sensitivity and insulin action. ISR derived from C-peptide concentration is an example of nonparametric Bayesian model selection where a proposed ISR time-course is considered to be a ''model''. An inferred value of inaccessible continuous variables from discrete observable data is often problematic in biology and medicine, because it is a priori unclear how robust the inference is to the deletion of data points, and a closely related question, how much smoothness or continuity the data actually support. Predictions weighted by the posterior distribution can be cast as functional integrals as used in statistical field theory. Functional integrals are generally difficult to evaluate, especially for nonanalytic constraints such as positivity of the estimated parameters. We propose a computationally tractable method that uses the exact solution of an associated likelihood function as a prior probability distribution for a Markov-chain Monte Carlo evaluation of the posterior for the full model. As a concrete application of our method, we calculate the ISR from actual clinical C-peptide measurements in human subjects with varying degrees of insulin sensitivity. Our method demonstrates the feasibility of functional integral Bayesian model selection as a practical method for such data-driven inference, allowing the data to determine the smoothing timescale and the width of the prior probability distribution on the space of models. In particular, our model comparison method determines the discrete time-step for interpolation of the unobservable continuous variable that is supported by the data. Attempts to go to finer discrete time-steps lead to less likely models.
INTRODUCTION
The inference of continuous quantities from small numbers of measurements is ubiquitous in medicine and biology. Bayesian model comparison is ideally suited for such tasks because it automatically invokes Occam's principle and balances goodness-of-fit against the complexity of the model (1) (2) (3) . However, Bayesian methods are computationally intractable for high dimensional problems as they require integration over the parameter space. Hence, many theoretical advances in Bayesian inference (4) have not yet been fully exploited in applications. Here we show that such integrals become numerically tractable if a suitable approximation of the prior probability distribution can be explicitly calculated to provide an initial condition for a Markov-chain Monte Carlo (MCMC) evaluation of the model posterior probabilities (i.e., Bayes factors). MCMC will generally not converge to a meaningful result unless a good initial condition is specified. For concreteness, we present the application of this general methodology to a concrete example of clinical relevance with data from human subjects in this article.
The accurate determination of pancreatic b-cell function as manifested in the insulin secretion rate (ISR) is clinically important in assessing the contribution of abnormal insulin secretion to diseases related to reduced insulin sensitivity and insulin action such as prediabetes and diabetes mellitus (5, 6) . The extraction of insulin secreted into the portal vein by the liver precludes the direct measurement of the ISR from peripherally sampled insulin concentration (7, 8) . C-peptide is cosecreted in an equimolar amount with insulin by pancreatic b-cells and the concentration is negligibly affected by first-pass hepatic metabolism (9) . The ISR is then equivalent to the C-peptide secretion rate, which can be found from the plasma C-peptide time-course and the C-peptide clearance rate. The relationship between C-peptide and insulin can be quantified using a twocompartment model of plasma and extravascular C-peptide allowing for the inference of ISR by solving an inverse problem. C-peptide clearance by the kidneys is dependent on the ISR per se and changes in C-peptide clearance are not measurable in the urine (10) . We concentrate on the two-compartment model, leaving refinements to account for kidney function for future work. Thus, for our purposes, the problem comes in attempting to infer the continuous secretion rate from incomplete discretized C-peptide measurements.
The traditional method of solving this inverse problem is to either reduce the dimensionality by using a parametric form for the ISR or use some interpolation method to infer the missing data. A major problem with this approach is that the formula for inferring the ISR from the discrete C-peptide measurements involves the numerical differentiation of an interpolated C-peptide time-course. As is well known, the numerical derivative of an interpolated function depends sensitively on the interpolation. Thus, these methods are ad hoc in the sense that the constraints are imposed extemporaneously to the data and it is unclear how much smoothness or continuity the data actually support. A more suitable situation is to let the data, combined with the minimal desideratum for the ISR (namely, continuity of the secretion profile), predict the missing data. Bayesian model comparison is a principled means of predicting data at unsampled time points because it balances the complexity of the model with goodnessof-fit to the experimental data. On the other hand, it also requires integration over high-dimensional spaces that is usually neither analytically nor numerically tractable. We take a two-step strategy where we consider a reduced problem that can be analytically solved and then use this solution as a starting point for a numerical MCMC integration.
ISR quantitative models have been considered extensively in the literature. The secretion and disposition characteristics of C-peptide are incorporated into a model, as proposed by Eaton et al. (11) (Fig. 1 ). Plasma C-peptide and extravascular C-peptide concentrations vary according to a two-compartment model with dynamics obeying
where C is the plasma C-peptide concentration, Y is the extravascular C-peptide concentration, and S(t) is the rate of production of C-peptide, i.e., the secretion rate from the pancreas to be inferred. The kinetic parameters k 1 , k 2 , and k 3 could be calculated on an individual basis by measuring the rate of disappearance of injected C-peptide from the plasma (11), but such data are not always available. However, it is possible to rely on standard parameters calculated from individual clinical characteristics following Van Cauter et al. (12) . This classic model does not account for ISR-dependent renal uptake of C-peptide, but we postpone an actual change in the model structure for the future. Our aim in this article is to present a methodology to obtain the ISR function from Bayesian functional integrals applied to this standard C-peptide model. Equations 1 and 2 can be solved in closed form for the secretion rate, S, in terms of a given C-peptide concentration profile, C. This is the classic approach taken, and it yields the theoretical solution
where C 0 is the C-peptide concentration at the initial time, t 0 ¼ 0. In practice, the C-peptide concentration profiles can only be measured discretely according to an experimental protocol. Hence, an interpolation step is required to estimate the integral and derivative in Eq. 3, and the numerical derivative, in particular, depends on the interpolation method used. Our two-step approach to bypass numerical interpolation is to perform a Bayesian functional integral over possible ISR profiles S(t), weighted by requiring 1), consistency with C-peptide data, and 2), continuity in the secretion profile. Regarding S(t) as a model, the posterior probability of S(t) is given by Bayes' theorem,
with P[data j S(t)] as the probability of the C-peptide data arising from a particular S(t), and P[S(t)] as the a priori probability of that S(t), giving a higher probability to a smoother S(t). For our prediction, we take the expectation value of S(t) over the posterior probability,
where DSðtÞ P½SðtÞjdata is the measure for the functional integral over all possible ISR functions S(t) We will assume DS(t) to be the product (over the time points t) of the standard translation invariant Lebesgue measure for S(t). We show how to compute this functional integral by using an exact solution to an associated problem in the Methods. 
METHODS
We implement the exact numerical problem as follows: Assuming the C-peptide concentration is measured at discrete times t 0 , t 1 , ., t m , we define the vectorc , wherẽ
T is the nonbasal secretion rate at n evenly spaced time points from t m /n to t m . K 0 is an n Â n lower-triangular matrix with t m /2n along its main diagonal and with i th row, j th column entries, K 0 ij , below the diagonal given by
where l 1 and l 2 are the eigenvalues, with corresponding eigenvectors,
of the system matrix of the differential system. Equation 6 employs the trapezoidal rule for numerical integration (13) . Thus, the integral is numerically evaluated as a sum of terms using
for each time step. M is an m Â n matrix that is used to select the entries of K 0s that coincide with the C-peptide measurements, i.e., the i th entry is selected if t m i/n˛{t 1 , t 2 ,., t m } because the experimental data we are using only samples C-peptide values at specific time points.
In writingc ¼ MK
0s
, we assume the discrete times chosen for the secretion rate include all times, t i , for which C-peptide measurements are made. If that is not the case,c is simply redefined to exclude those entries that are omitted by the scheme. To simplify notation, we define the m Â n matrix K ¼ MK 0 . We define a matrix, F, to perform numerical differentiation. We use a three-point formula for differentiation (13) . Thus, the derivative matrix
This solution provides the nonbasal secretion rate. The total secretion rate,S, is equal to k 3 C 0 at time t 0 , because the system is assumed to be in equilibrium at that time, and s i þ k 3 C 0 at each later time point, t i , in the discretization scheme. As this is all linear algebra to this point, nothing prevents the predicted secretion rate from having nonpositive values.
The measure for the functional integral, Eq. 5, may be written in the form DS(t) exp (ÀbE), with a cost function E given by (k$k is the ' 2 norm)
The first term in E is Àln(P[data j S(t)]), and the remaining two terms correspond to Àln(P[S(t)]). We explain the meaning of each of these terms in turn. K is the matrix representing the linear solution of Eqs. 1 and 2, giving the C-peptide concentration as a function ofs. Thus, this term is a measure of goodness of fit, measuring the deviation of the predicted C-peptide from a given ISR models from the experimentally observedc: The second term measures continuity as F is a matrix representing the linear operation of differentiation. Thus, this term is a constraint on the difference between successives values in a given ISR model, giving higher probability tos values that are smoother. In particular, this term connects integrand variables in the product that measure DSðtÞ ¼ Ds; and implies that the values in the ISR are not independent random variables. The last term enforces the constraint thats is nonnegative, according a vanishing probability tos with negative values at any time point. This is the term that renders an exact Gaussian evaluation of the integral impossible, as it is not quadratic ins.
The exact functional form of the last term in Eq. 7 does not affect the results. The normalizations of these terms are dictated by experimental uncertainties: the intrinsic fluctuations of the experimental data,s c , and the fluctuations in the secretion rate,s s , propagated through the model from the magnitude of the fluctuations observed in the experimental data (details below). The magnitude of d is 10 À5 , which is well below the uncertainty in experimental measurements for the data presented in this article. The number of time points at which we evaluates is also a model parameter. In particular, it is determined by the discretization, and in the following, we show that the appropriate step size, h, of the discretization scheme chosen fors, is also picked out by the Bayesian model selection. The weighting factor, g, in Eq. 7 is the final model parameter in the set that distinguishes different models, X h,g , in the model comparison.
The functional integral in Eq. 5 would be impossible due to the large number of variables in the integration. For example, for a time step of h ¼ 0.5 min, there are~240 values in the ISR time-course. However, we are able to find the maximum of the measure exactly by neglecting the nonnegativity constraint in a preliminary calculation. In this preliminary calculation, we suppose that we want to solvec À Ks ¼ 0 exactly, because this is just a matrix representation of the linear differential equations of the twocompartment model (Eqs. 1 and 2). Because this is an underdetermined system, we can also require that the solution minimizes kFs 2 k, which is exactly the second term in Eq. 7, favoring continuous secretion profiles. This constrained linear algebra problem can be explicitly solved by means of Lagrange multipliers, n, with an associated Hamiltonian function,
Now, it follows by multiplying the transpose of the second equation by
but thenc
Solving forñ;ñ
and, therefore, multiplying both sides by (
We minimize Eq. 7 and fit each model separately to data from each of the subjects in our study. All the points of a secretion rate profile are varied collectively in the optimization process using a Markov-chain Monte Carlo method with parallel tempering (2) . Optimizations are performed for each model considered using 10 uniformly spaced values (100-1000) for the tempering parameter, b, and the corresponding updating probability, e ÀbE . Simulations begin with an initialS calculated from Eq. 13 with any negative values replaced by 2d. After equilibration, 10 5 iterations are performed for each tempering parameter, and statistics, such as hSi b and hEi b , are calculated.
The probability distribution for the model conditional on the data, D, is denoted as P(X h,g j D). We calculate the log probability that the model describes the data for each individual, i, and across all individuals as
The model with the largest log-likelihood is chosen as the winning model with optimal parameter values on a population basis. The advantage of this method is that it balances goodness of fit, smoothness, and nonnegativity while fitting the models to the data from each individual separately, all within the same numerical procedure. The method also removes the subjectiveness of choosing how to interpolate the C-peptide profile and how to discretize the secretion rate.
We apply the improved model of the ISR to C-peptide data from hyperglycemic glucose clamp studies. . After a 12-h overnight fast, a hyperglycemic glucose clamp was initiated with a 10-min priming infusion of 20% dextrose to raise plasma glucose concentration to 13.9 mM. After the priming dose the infusion rate was adjusted every 5 min to maintain plasma glucose concentration at 13.9 mM. At 45 min after the start of the dextrose infusion, 5 g of arginine monohydrochloride in 50 mL of normal saline was administered over 2 min as a priming dose and a continuous infusion at 15 g/m 2 /h was given for the remainder of the 2-h period. Seventy-five minutes after the start of the dextrose infusion, subjects consumed a liquid fat drink (37.5 mL) containing 25 g of corn oil (Lipomul; Upjohn, Kalamazoo, MI). C-peptide measurements were used to calculate the secretion rates over the 0-120 min time interval. For each individual, the i th component ofs c was calculated as C i multiplied by the ratio of the standard deviation to the mean of the À10, À5, and 0 min C-peptide measurements.
The model is implemented in MATLAB (The MathWorks, Natick, MA).
RESULTS

Fig. 2 shows the mean C-peptide profile of actual clinical data obtained from hyperglycemic clamp experiments on 45 human subjects (14-16). The vertical bars at 45 min
and 75 min represent the times at which arginine administration commenced and a liquid fat drink was administered, respectively. The theoretical solution in Eq. 3 depends sensitively on the interpolation scheme one uses, as shown in Fig. 3 . Note the appearance of negative S(t) predictions in Fig. 3 as the smoothness of the interpolation scheme increases. Alternatively, these data can be immediately converted to preliminary S(t) profiles (the mean of these profiles is shown in Fig. 4 ) using linear algebra (see Methods) and subject-dependent parameters calculated according to Van Cauter et al. (12) . These preliminary profiles sometimes exhibit negative values, which is an artifact of the linear algebraic exact solution of an underdetermined problem with the smoothness constraint. Truncating negative values to an arbitrarily small positive number and using these preliminary S(t) profiles as starting values allow MCMC evaluation of the functional integral, with rapid equilibration as shown in Fig. 5 . The Bayesian prior probability distribution is comprised of three components: enforcing the goodness-of-fit in predicting the observed C-peptide data, continuity of the deduced ISR profile, and the positivity of the deduced ISR profile. As evident in Fig. 6 , the relative impact of these desiderata in the equilibration process changes.
We evaluated a variety of models to ascertain the most likely step size in the discrete functional integrals and for the relative weighting of the different components of the Bayesian prior probability distribution. Fig. 7 shows the log-likelihood of models (Bayes factors) with different weights accorded to smoothness versus goodness-of-fit, as a function of step-size. The most likely model for this population of subjects has h ¼ 1 min and g ¼ 2. The subject mean S(t) profile, deduced from the individual Bayesian prior probability distribution-weighted mean S(t) profiles over MCMC simulations, is shown in Fig. 8 . As is evident, the predicted S(t) is not as smooth as the exact solution, but is positive at all values. Fig. 9 illustrates the C-peptide profiles that would be predicted from the S(t) profiles in Figs. 3 and 8 according to the two-compartment model.
We note the physiologically incorrect prescient increase in the S(t) profile before the 45-min mark in Fig. 8 . The increase is a result of the smoothness constraint being applied across the physically discontinuous situation involving the externally infused arginine. To account for such experimental conditions, we must use all the information available about the experiment, and impose a discontinuity by considering the time intervals separately and calculating the S(t) profiles sequentially, using the final time point from one interval as the initial condition in the next. Figs. 10 and 11 illustrate the S(t) profiles and corresponding C-peptide profile predictions, respectively, for the first 40 min of the hyperglycemic glucose clamp data.
DISCUSSION
It is well established that insulin secretion is a pulsatile process (17) . When data points are sparse, methods that use interpolation and Eq. 3 to estimate secretion rates tend to flatten the secretion profile, or result in large value changes, evident in Fig. 3 . In contrast, our method shows oscillatory behavior consistent with sparse data points, but no artificial flattening of the secretion profile (Fig. 8) . Unfortunately, we have no data on the ''ground'' truth for the insulin secretion rate. Such data would require a portal vein catheterization to directly compare insulin secretion with the C-peptide based indirect measurement. This is a major invasive clinical procedure, and it would be unethical to ask healthy humans to undergo such an invasive procedure without medical necessity. Thus we cannot state FIGURE 4 ISR profile prediction calculated using Eq. 13 for the C-peptide profile data referred to in Fig. 2 . ISR profiles were calculated for each individual and then averaged to yield the curve shown here. (Error bars) Mean 5 SE. Example of the total cost equilibrating during an MCMC simulation. Total cost is calculated using Eq. 7, with h ¼ 1 and g ¼ 2, and the initial ISR profile is calculated using Eq. 13. C-peptide data from Subject 2 was used for this example. definitively that our method gives results that are closer to biological reality. However, the 45 clinical subjects were categorized by their glucose tolerance into three groups-normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetics (T2DM). As expected, these three groups exhibit major differences in their ISR profiles (see Fig. 12 ). The only model that shows physiologically realistic behavior in the computed ISR is our model. The Hermite interpolation and spline show a decrease in the ISR in NGT subjects at the beginning of glucose infusion, whereas the linear interpolation shows a slower initial rise for NGT compared to IGT and T2DM. The spline interpolation gives negative ISR values at the beginning and~28 min for NGT subjects. The sensitivity of the other models to data point removal is also evident in the period between 0 and 5 min. Thus our model is a qualitative and quantitative improvement in the computation of a physiologically realistic ISR.
Combining parallel tempering for model comparison and our functional integral evaluation, we can determine the optimal step size, h, and the optimal weight for the prior probability distribution on the space of function ''models'', g, as in Fig. 7 , in an entirely data-driven manner. This is a simple way to avoid overfitting the data and taking biologic variation into account. More detailed or more precise data can be used in an incremental manner to continue refining the choice of optimal parameters, a major factor in favor of Bayesian approaches. The methodology used here illustrates the practicality of using functional techniques in biological applications, given the availability of computing power. Of course, several techniques are available for speeding up the numerical evaluation of the MCMC sampling, such as using a nontrivial Hastings factor or level-set representations. For our relatively small clinical sample of subjects, this was not necessary. The biases inherent in making choices to avoid underfitting or overmodeling can be partially avoided by being more inclusive in model evaluation, letting the available data set determine the most likely model. Moreover, such detailed results may show biological variability, evident in Fig. 8 , which is more realistic than idealizations.
We initially attempted to address this problem by means of Gaussian process models, with continuous function determination without a discretization step. In our case, although the linear algebra readily admits an h / 0 limit, the next step of evaluating the functional integral in the continuous case with the positivity constraint in place is not tractable. We therefore presented here the discrete analog of Gaussian process models. As is standard in Gaussian process models, a length scale is determined by Bayesian model comparison. In our case, that length scale is the discretization scale h supported by the data. From the clinical data uncertainties evident in the ISR computations, it is clear the discretization in our approach is not the limiting factor in the accuracy of the ISR (see Fig. 12 ).
We have emphasized that our method gives us limits on how well one can expect to infer the unobserved variable from discrete constraints, because the optimal discretization time step h is also determined by Bayesian model selection. We use linear interpolation for values of the ISR between these time steps, but the important point is that one could use any interpolation as long as one keeps in mind that any such interpolation is not constrained by the data. In other words, the observations only determine differences in ISR values for time points that are farther apart than h. The ISR that we find is not smooth compared to splines or interpolation. It is, however, taking into account biologic fluctuations in the data for each individual subject. Assuming that the ground truth secretion rate is smooth is not justified by clinical experience for most hormones for which such a comparison is practical.
The applicability of this methodology is more general than the linear problem utilized in the example of the ISR explicated here. Indeed, our method is applicable to nonlinear problems with the following characteristics: Experimental data at discrete time points, C(t i ) as a constraint on a continuous unobserved variable, S(t) that determines the dynamics of C(t) by a general functional F [C(t), S(t)] ¼ 0. Interpolating the experimental data to a functionCðtÞ; we can linearize the functional dependence as 
FIGURE 12 Average predicted C-peptide profiles from 45 subjects separated into normal glucose tolerance (NGT, bold line), impaired glucose tolerance (IGT, regular line), and type 2 diabetes (T2DM, dotted line) for the four models.
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Expanding in powers of dC and dS after approximately solving forSðtÞ in terms of the given functionCðtÞ; we arrive again at an underdetermined linear problem to which the methods of this article are applicable mutatis mutandis, F hC ðtÞ;SðtÞ i þ dF dC dCðtÞ þ dF dS dSðtÞ ¼ 0; (15) with the appearance of the inhomogeneous first term due to the fact that we do not require an exact solution of F ½CðtÞ;SðtÞ ¼ 0: Because Eq. 15 is again a linear problem, a smoothness-maximizing solution to the underdetermined problem is easily found (see Methods). The smoothness maximization is applied toS þ dS; of course, but the method remains applicable with trivial algebraic changes. Iteration to improve choices ofCðtÞ andSðtÞ used as starting points is also possible.
